3-(3-Methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride

Catalog No. :
ACIAOU284
CAS No. :
2924465-43-8
Molecular Formula :
C19H26ClN5O3
Molecular Weight :
407.90

IUPAC Name:3-(3-methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride

3-(3-Methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(3-Methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride
IUPAC Name3-(3-methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride
Molecular FormulaC19H26ClN5O3
Molecular Weight407.90
SMILESCNC1CCCN(C2=CC=C3C(=C2)N(C)C(=O)N3C2CCC(=O)NC2=O)C1.Cl
InChI KeyCHCVDRZPFHSTBX-UHFFFAOYSA-N
Synonym3-(3-methyl-5-(3-(methylamino)piperidin-1-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride;2,6-Piperidinedione, 3-[2,3-dihydro-3-methyl-5-[3-(methylamino)-1-piperidinyl]-2-oxo-1H-benzimidazol-1-yl]-, hydrochloride (1:1)
CAS No.2924465-43-8

Synthetic Route by SureRoute

1. ACIAOU284 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACIAOU284 route product structure diagram
    ACIAOU2842924465-43-8
Inquiry

2. ACIAOU284 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIAOU284 route product structure diagram
    ACIAOU2842924465-43-8
Inquiry

Comments (0)